NCT03961516View on ClinicalTrials.gov

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

CompletedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Cystic FibrosisCystic Fibrosis-related DiabetesCystic Fibrosis Liver DiseasePancreatic SteatosisHepatic Steatosis
Interventions
DEVICE

Frequently Sampled Oral Glucose Tolerance Test and CGM

Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.

RADIATION

MRI Pancreas and Liver

Patients will undergo an MRI of the pancreas and liver

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER

NCT03961516 - Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis | Biotech Hunter | Biotech Hunter